Lilly Forteo
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's Endocrinologic and Metabolic Drugs Advisory Committee will review the recombinant parathyroid hormone Forteo (teriparatide) on July 27 for treatment of osteoporosis